Синдром гиперпролактинемии у детей и подростков: оптимизация методов диагностики и лечения
![Диссертация: Синдром гиперпролактинемии у детей и подростков: оптимизация методов диагностики и лечения](https://westud.ru/work/2519576/cover.png)
Основные положения диссертационной работы доложены на XIV, XV и XVI конгрессах педиатров России с международным участием «Актуальные проблемы педиатрии» (Москва, 2010, 2011, 2012), на XVII и XVIII Российских национальных конгрессах «Человек и лекарство» (Москва, 2010, 2011), 49th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE) (Прага, 2010), на IV городской… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. СИНДРОМ ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ — ПРОБЛЕМЫ ДИАГНОСТИКИ И ТЕРАПИИ ОБЗОР ЛИТЕРАТУРЫ)
- 1. 1 ПРОЛАКТИН-МНОГОФУНКЦИОНАЛЬНЫЙ ГОРМОН АДЕНОГИПОФИЗА
- 1. 2 КЛИНИЧЕСКАЯ К ЛАС СИФИКАЦИЯ ГИПЕРПРОЛАКТИНЕМИИ
- 1. 3 ФИЗИОЛОГИЧЕСКИЕ ПРИЧИНЫ ГИПЕРПРОЛАКТИНЕМИИ
- 1. 4 ПАТОЛОГИЧЕСКИЕ ПРИЧИНЫ ГИПЕРПРОЛАКТИНЕМИИ 20 1 5 КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ ГИПЕРПРОЛАКТИНЕМИИ РАЗЛИЧНОГО ГЕНЕЗА У ДЕТЕЙ И
- ПОДРОСТКОВ
- 1. 6 ДИАГНОСТИКА СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ
- 1. 7 ЛЕЧЕНИЕ СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ
- ГЛАВА 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- ГЛАВА 3. РЕЗУЛЬТАТЫ СОБСТВЕННЫХ ИССЛЕДОВАНИЙ И ИХ ОБСУЖДЕНИЕ
- З 1 КЛИНИЧЕСКАЯ ХАРАКТЕРИСТИКА ПАЦИЕНТОВ
3 2 СРАВНИТЕЛЬНАЯ ХАРАКТЕРИСТИКА СИМПТОМОВ ДЕБЮТА СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ РАЗЛИЧНОГО ГЕНЕЗА У ДЕВОЧЕК З 3 СРАВНИТЕЛЬНАЯ ХАРАКТЕРИСТИКА СИМПТОМОВ ДЕБЮТА СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ РАЗЛИЧНОГО ГЕНЕЗА У МАЛЬЧИКОВ
3 4 ДИАГНОСТИКА ГЕНЕЗА СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ 84 3 5 СОСТОЯНИЕ УГЛЕВОДНОГО И ЛИПИДНОГО ОБМЕНА У ДЕТЕЙ И ПОДРОСТКОВ С СИНДРОМОМ ГИПЕРПРОЛАКТИНЕМИИ
3 6 СОСТОЯНИЕ ПОЛОВОГО СТАТУСА У ДЕТЕЙ И ПОДРОСТКОВ С СИНДРОМОМ ГИПЕРПРОЛАКТИНЕМИИ ОПУХОЛЕВОГО ГЕНЕЗА
3 7 МИНЕРАЛЬНАЯ ПЛОТНОСТЬ КОСТНОЙ ТКАНИ (МПК) У ДЕТЕЙ И ПОДРОСТКОВ С СИНДРОМОМ ГИПЕРПРОЛАКТИНЕМИИ РАЗЛИЧНОГО ГЕНЕЗА
3 8 ЛЕЧЕНИЕ СИНДРОМА ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ
Список литературы
- Балаболкин М.И., Клебанова Е. М., Креминская В.М.
- Дифференциальная диагностика и лечение эндокринных заболеваний. -М.: Медицина, 2002: 94−107.
- Вакс В.В. Гиперпролактинемия: причины, клиника, диагностика и лечение. СошШшт-МесИсит 2001- № 11, Том 3.
- Горобец Л.Н. Нейроэндокринные побочные эффекты антипсихотических препаратов: итоги и перспективы. Психофармакология и биологическая наркология 2008- 8(1−2, часть 1): 2321−22.
- Дедов И.И., Мельниченко Г. А., Романцова Т. И. Синдром гиперпролактинемии. М.: Триада, 2004- 252−57.
- Дедов И.И., Петеркова В. А. Руководство по детской эндокринологии. -М.: Универсум Паблишинг, 2006- 125−27.
- Дзеранова Л.К., Бармина И. И. Особенности диагностики и лечения гиперпролактинемического синдрома. Журнал Эффективная фармакотерапия в эндокринологии 2009- 1: 1−7.
- Дзеранова Л.К. Синдром гиперпролактинемии и успехи медикаментозной терапии / В кн.: Нейроэндокринология Под ред. Е.И. Маровой//Ярославль: ДИА-пресс, 1999: 201−240.
- Дзеранова Л.К. Синдром гиперпролактинемии у женщин и мужчин: клиника, диагностика и лечение: автореф. дисс.. д.м.н. Москва, 2008.-56с.
- Дэниеле Г., Мартин Д. Нейроэндокринная регуляция- болезни передней доли гипофиза и гипоталамуса // Внутренние болезни / Под ред. Т. Р. Харрисона. -М.: Медицина. 1997- с. 19−66.
- Мазеркина Н.А., Петеркова В. А., Горелышев С. К. Краниофарингиома у детей: эндокринные нарушения, их диагностика и лечение. М.: 2007- 25 с.
- Мельниченко Г. А., Марова Е. И., Дзеранова Л. К., Вакс В. В. Гиперпролактинемия у женщин и мужчин, пособие для врачей. М.: 2007- с. 22−23.
- Пальцев М.А., Кветной И. М. Руководство по нейроиммуноэндокринологии, 2 издание. М.: Медицина, 2008. — 512 с.
- Семичева Т.В. Преждевременное половое развитие (клинические, гормональные, молекулярно-генетические аспекты: автореф. дисс.. д.м.н. Москва, 1998. — С. 26.
- Храмцова С.Н., Щеплягина Л. А., Арсеньева Е. И., Алатырцев В. В., Моисеева Т. Ю. Возрастные закономерности изменения биохимических маркеров костного ремоделирования у детей 5−16 лет. Вопросы современной педиатрии 2006- 5: 620.
- Чарльз Г. Д. Брук, Розалинд С. Браун Руководство по детской эндокринологии. Перевод с англ. под редакцией Петерковой В. А. -М.: 2009- 290−91.
- Шишкова В.Н. Ожирение и гиперпролактинемия. Consilium medicum: Эндокринология 2010- 12: 83−6.
- Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS
- Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary. 2009- 12: 186−189.
- Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000- 61(8): 5−11.
- Artese R, D’Osvaldo, DH, Molocznik I, Benencia H, Oviedo J, Burman JA & Basso A. Pituitary tumors in adolescent patients. Neurological Research. 1998- 20: 415−417.
- Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2002−2:836−849.
- Asai-Sato M, Okamoto M, Endo M et al. Hypoadiponectinemia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006- 53(4): 555−62.
- Astafeva LI, Kadashev BA, Kutin MA, Kalinin PL. Complications of treatment of prolactinoma by dopamine agonists. Zh Vopr Neirokhir Im N NBurdenko. 2011- 75(2): 41−50.
- Bachelot A, Bin art N. Reproductive role of prolactin. Reproduction 2007- 133: 361−369.
- Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R. Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 1991- 72: 602−6.
- Barkan AL, Chandler WF. Giant pituitary prolactinomawith falsely low serum prolactin: the pitfall of the «high-dose hook effect»: case report. Neurosurgery 1998- 42: 913−16.
- Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996−2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003- 88: 4709−19.
- Barrio R, Roger M, Chaussain JL, Job JC. Prolactin-secreting pituitary adenomas in children and adolescents (Study of a series of 8 cases). Arch Fr Pediatr. 1979- 36(8): 785−93.
- Bayrak A, Saadat P, Mor E, Chong L, Paulson R, Sokol R. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005- 84: 181−85.
- Ben-Jonathan N. Hypothalamic control of prolactin synthesis and secretion. In: Horseman ND, ed. Prolactin. Boston: Kluwer. 2001- 1−24.
- Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001- 22(6): 724−63.
- Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006- 17(3): 110−116.
- Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 1996- 17: 639−669.
- Beran RG. Prolactinoma: are dopamine agonists still first choice? Intern Med J. 2011- 41(10): 757.
- Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011- 14(3): 199−207.
- Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S.
- Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010- 131: 530−35.
- Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992- 75: 692−97.
- Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A. Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 1991- 78: 996−1001.
- Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxford) 2005- 63: 26−31.
- Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998- 19: 225−268.
- Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab 2006- 2: 408−412.
- Bougneres P, Pantalone L, Linglart A, Rothenbuhler A, Le Stunff C.
- Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J Clin Endocrinol Metab 2008- 93: 3971−80.
- Bracero N, Zacur HA. Polycystic ovary syndrome and hyperprolactinemia. Obstet Gynecol Clin North Am. 2001- 28: 77−84.
- Brada M, Jankowska P. Radiotherapy for pituitary adenomas. Endocrinol Metab Clin North Am 2008- 37: 263−275.
- Brandebourg TD, Hugo ER, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007- 9:364−377.
- Burdman JA, Pauni M, Heredia Sereno GM, Bordyn AE. Estrogen receptors in human pituitary tumors. Horm Metab Res. 2008- 40: 524−27.
- Bussone G, Usai S, Moschiano F. How to Investigate and Treat: Headache and Hyperprolactinemia. Curr Pain Headache Rep. 2012 May 26. Epub ahead of print.
- Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab 1997- 82(2): 585−9.
- Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009- 19: 373−382.
- Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 1998- 73: 1046−1052.
- Cannavo' S, Curto" L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999- 22:354 359.
- Castelo-Branco C, Rovira M, Pons F et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996- 23: 307−12.
- Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG. Some forms of big big prolactine behave as complex of monomelic with an immunoglobulin G in patients with macroprolactinoma or prolactinomas. J Clin Endocrinol Metab 1995- 80: 2342−6.
- Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004- 65: 187−190.
- Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008- 11: 141−6.
- Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005- 8: 3−6.
- Coculescu M, Simionescu N, Oprescu M, Alessandrescu D.
- Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect. Endocrinology. 1983- 21: 157−168.
- Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001- 11: 435−440.
- Cohen PR, Robinson FW, Gray JM. Prolactinoma can be associated with gynecomastia. Skinmed. 2010- 8(4): 201−2.
- Colao A, Di Sarno, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003- 148: 325−331.
- Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003- 349:2023−2033.
- Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G.
- Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxford) 2007- 67: 426−433.
- Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G.
- Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Jclin Endocrinol Metab 2000- 85: 22 472 252.
- Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997- 82: 876−883.
- Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxford) 2000- 52: 319−27.
- Colao A, Grasso LF, Pivonello R, Lombardi G. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother. 2011- 12(10): 1561−70.
- Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998- 83:2777−2780.
- Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet. 1998- 352: 1455−1461.
- Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother 2000- 1: 555−574.
- Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol. 2011- 7(5): 267−78.
- Colao A, Vitale G et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metabol 2004- 89(4): 1704−11.
- Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006- 45: 771−791.
- Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol 1991- 125(4): 392−6.
- Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006- 91: 4769−75.
- Davis V, Rosenbloom AL. Metabolic effects of antipsychotic drugs. Pediatric Diabetes. 2006- 7(3): 176−186.
- Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira
- AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010- 95:43−51.
- Delemer B. MEN1 and pituitary adenomas. Ann Endocrinol (Paris). 2012- 73(2): 59−61.
- Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009- 160:747−752.
- Delgrange E, Donckier J, Maiter D. Hyperprolactinemia as a reversible cause of weight gain in male patients? Clin Endocrinol (Oxford) 1999- 50(2):271−2.
- Delgrange E, Troullas J, Maiter D, Donckier J, Tourniare J. Sex-related difference in the groth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997- 82(7): 2102−7.
- Deligeoroglou E, Tsimaris P. Menstrual disturbances in puberty. Best Pract Res Clin Obstet Gynaecol. 2010- 24(2): 157−71.
- De Menis E, Visentin A, Billed D, Tramontin P, Agostini S, Marton E, Conte N. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest. 2001- 24: 92−97.
- De Rosa M, Zarrilli S, Di Sarno A, Milano N, Gaccione M, Boggia B, Lombardi G, Colao A. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 2003- 20: 7582.
- Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A.
- Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of Clinical Endocrinology and Metabolism. 2001- 86(6): 5256−61.
- Doknic M, Pekic S, Zarkovic M et al. Dopaminergic tone and obesity: and insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002- 147(1): 77−84.
- Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, Lania AG. Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest 2007- 37: 552−557.
- Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2010- 17(9): 1783−1788.
- Elshalbr H, Lew A, Paul W, Sundmarp V. Hyperprolactinemia. J Biol Chem 1991- 4(266): 22 919−22 925.
- Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004- 29(5):833−846.
- Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxford) 2009- Dec 18. Epub ahead of print.
- Eren E, Yapici? akir ED, Ceylan LA, Saglam H, Tarim O. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011- 3(2): 65−9.
- Eric R Hugo, Dana C Borcherding, Keith S Gersin, Jean Loftus, Nira Ben-Jonathan Prolactin Release by Adipose Explants, Primary Adipocytes, and LS14 J. Clin. Endocrinol. Metab. 2008- 93: 4006−4012.
- Fabre-Brue C, Roth E, Simonin G, Palix C, Martin PM, Brue T. Macroprolactinemia: a cause of hyperprolactinemia in childhood. J Pediatr Endocrinol Metab. 1997- 10: 411−7.
- Faglia G. Should dopamine agonist treatment for prolactinomas be lifelong. Clin Endocrinol (Oxford) 1991- 34: 173−174.
- Fahie-Wilson MN. In Hyperprolactinemia, testing for macroprolactin is essential. Clinical Chemistry 2003- 49: 1434−36.
- Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005- 42: 175−192.
- Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG. The lipoprotein profile of women with hyperprolactinemic amenorrhoea. Hum Reprod 1999- 14: 285−287.
- Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011- 96(6): 1633−41.
- Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab. 2000- 13: 261−267.
- Fideleff HL, Boquette HR, Suarez MG, Azaretzky M. Prolactinoma in Children and Adolescents. Horm Res. 2009- 72:197−205.
- Fideleff HL, Holland ME, Chervin A, Gurucharri C, Sinai I Treatment of hyperprolactinemic amenorrhea with cabergoline. Medicina (B Aires) 1997- 57(6): 657−61.
- Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P.
- Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res. 2000- 53: 16−19.
- Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxford). 2010- 72: 377−382.
- Ferreira MF, Sobrinho LG, Pires JS, Silva ME, Santos MA, Sousa
- MF. Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology. 1995- 20(1): 53−63.
- Fleenor DE, Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology. 2001- 142: 2805−2810.
- Flint DJ, Binart N, Kopchick J, Kelly P. Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 2003- 6: 97−102.
- Forsyth IA, Wallis M. Growth hormone and prolactin-molecular and functional evolution. J Mammary Gland Biol Neoplasia. 2002- 7: 291−312.
- Foss MC, Paula F J, Paccola GM, Piccinato CE. Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxford) 1995- 43(6): 721−6.
- Frantz AG, Kleinberg DL. Prolactin: evidence that it is separate from growth hormone in human blood. Science 1970- 170: 745−47.
- Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML. Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011- 96(4): 894−904.
- Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000- 80(4): 1523−631.
- Fuglsang J, Skjaerbaek C, Frystyk J, Flyvbjerg A, Ovesen P. Alongitudinal study of serum adiponectin during normal pregnancy. BJOG 2006- 113(1): 110−3.
- Furtado SV, Saikiran NA, Ghosal N, Hegde AS. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia. Pediatr Neurol. 2010- 42(1): 72−4.
- Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis M, Dimitriadis A. Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab. 2000- 13(4): 439−41.
- Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab. 2005- 18(9): 921−4.
- Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening formacroprolactin. J Clin Endocrinol Metab. 2005- 90:3927−3932.
- Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006- 27: 485−534.
- Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffm V, Bronstein MD. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab. 2006- 91: 1048−55.
- Goffin V, Bin art N, Touraine P, Kelly PA. Prolactin: the new biology of an old hormone. Annu Rev Physiol. 2002- 64:47−67.
- Goffin V, Kelly PA. The prolactin/growth hormone receptor family: structure/function relationships. J Mammary Gland Biol Neoplasia. 1997- 2:7−17.
- Gordon CM, Nelson LM. Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol. 2003- 15(5): 377−84.
- Gothi D, Joshi JM. Late onset hypoventilation syndrome: is there a spectrum of idiopathic hypoventilation syndromes? Indian J Chest Dis Allied Sci. 2005−47:293−97.
- Greenman Y, Tordijman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxford). 1998- 48: 547−53.
- Gualillo O, Lago F, Garcia M, Menendez C, Senaris R, Casanueva FF, Dieguez C. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology. 1999- 140: 5149−5153.
- Guitelman M. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long? Front Horm Res. 2006- 35: 88−101.
- Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol. 2007- 156:143−153.
- Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004- 64(20): 2291−2314.
- Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M.
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009- 161: 631−637.
- Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005- 8: 53−60.
- Harrington MH, Casella SJ. Pituitary tumors in childhood. Curr Opin Endocrinol Diabetes Obes. 2012- 19(1): 63−7.
- Harris J, Stanford PM, Oakes SR, Ormandy CJ. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med. 2004- 36(6): 414−25-
- Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci. 2003- 92(3): 171−7.
- Hattori N, Adachi T, Ishihara T, Shimatsu A. The natural history of macroprolactinaemia. Eur J Endocrinol. 2012- 166(4): 625−9.
- Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporosis Int. 2000- 11: 985−1009.
- Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest. 2002- 109: 277−283.
- Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008- 69(1): 32−44.
- Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxford). 2009- 70: 104−108.
- Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM. Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol. 1998- 178(5): 1010−5.
- Hoffman AR, Melmed S, Schlechte J. Patient guide to hyperprolactinemia diagnosis and treatment. J Clin Endocrinol Metab. 2011- 96(2): 35A-6A.
- Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinemia in adolescents. Journal of Clinical Psychophannacology. 2006- 2(26): 167 171.
- Hong JW, Lee MK, Kim SH, Lee EJ. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine. 2010- 37(1): 140−147.
- Hooghe-Peters EL, Dogusan Z, Hooghe R. In vitro effects of prolactin on the lympho-hemopoietic system. In: Horseman ND, ed. Prolactin. Boston: Kluwer. 2001- 317−339.
- Hugo ER, Brandebourg TD, Comstock CE, Gersin KS, Sussman JJ, Ben-Jonathan N. LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology. 2006- 147(1): 306−13.
- Hwang P, Guyda H, Friesen H. A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA. 1971- 68: 1902−6.
- Iglesias P, Diez JJ. Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists. QJM 2010 Jul 27. Epub ahead of print.
- Iyer P, Molitch ME. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocr Pract. 2011- 17(3): e55−8.
- Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J. Longterm follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxford). 1996- 45:299−303.
- Johnsen E, Kroken RA, Abaza M, Olberg H, Jorgensen HA.
- Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol. 2008- 28: 686−90.
- Johnston DG, Prescott RW, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB. Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med. 1983- 75: 868−874.
- Jummani R, Coffey BJ. Hyperprolactinemia in an adolescent with psychotic disorder on risperidone. J Child Adolesc Psychopharmacol. 2009- 19(6): 791−4.
- Kadioglu P, Oral G, Sayitoglu M, Erensoy N, Senel B, Gazioglu N, Sav A, Cetin G, Ozbek U. Aromatase cytochrome P450 enzyme expression in human pituitary. Pituitary. 2008- 11: 29−35.
- Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary. 1998- 1:69−81.
- Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman
- AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005- 90: 3089−3099.
- Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab. 1994- 79: 1135— 40.
- Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003- 27: 1081−1090.
- Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008- 159: 363−367.
- Kars M, Pereira AM, Smit JW, Romijn JA. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med. 2009- 20: 387−393.
- Kars M, Roelfsema F, Romijn JA, Pereira AM. Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol. 2006- 155: 523−534.
- Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009- 94: 2729−34.
- Katz ES, McGrath S, Marcus CL. Late-onset central hypoventilation with hypothalamic dysfunction: a distinct clinical syndrome. Pediatr Pulmonol. 2000- 29: 62−68.
- Keeler C, Dannies PS, Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol. 2003- 328: 1105−1121.
- Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab. 2009- 94: 2428−2436.
- Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab. 2009- 94: 2247−2249.
- Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010- 362:1219−26.
- Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003- 28(Suppl 2): 109−123.
- Kok P, Roelfsema F, Frolich M, Meinders E, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004- 89(9): 4445−9.
- Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE. Temozolomide therapy in amanwith an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol. 2007- 38:185−189.
- Kovacs K, Stefaneanu L, Horvath E, Buchfelder M, Fahlbusch R, Becker W. Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report. J Neurosurg. 1995- 82: 886−890.
- Krassas GE, Pontikides N, Kaltsas T. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Horm Res. 1999- 52: 45−48.
- Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008- 158: 11−18.
- Lamberts WJ, Mc. Leod RM. Hyperprolactinemia. Phisiol. Rev. 1990- 70(2): 279−308.
- Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008- 159: 1−5.
- Large V, Peroni O, Letexier D, Ray H, Beylot M. Metabolism of lipids in human white adipocyte. Diabetes Metab. 2004- 30: 294−309.
- Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012- 206(3): 213.
- Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006- 7: 518−520.
- Ling C, Svensson L, Ode’n В et al. Identification of functional prolactin (PRL) gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003- 88(4): 1804−8.
- Lorenson MY, Walker AM. Structure-function relationships in prolactin. In: Horseman ND, ed. Prolactin. Boston: Kluwer 2001- 189−217.
- Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-termoutcome. J Clin Endocrinol Metab. 2002- 87: 3180−3186.
- Lv H, Li C, Gui S, Zhang Y. Expression of estrogen receptor a and growth factors in human prolactinoma and its correlation with clinical features and gender. J Endocrinol Invest. 2012 — 35(2): 174−80.
- Madhusoodanan S, Moise D. Risperidone-induced hyperprolactinemia in adolescents: a case series. Journal of Clinical Psychiatry. 2006- 7(67): 1110−1113.
- Maguire GA. Повышение уровня пролактина при терапии антипсихотиками: механизмы действия и клинические последствия. Журнал психиатрия и психофармакология. 2006- 8(6): 32−34.
- Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol (Paris). 2012- 73(2): 90−8.
- Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008- 37: 67−99.
- Mann WA. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach. Eur J Clin Invest. 2011- 41(3):334−42.
- Martin N, Vinters H. Pathology and grading of intracranial vascular malformations. Intracranial vascular malformations / ed. by D.Barrow. -Park Ridge, IL, American Association of Neurological Surgeons. 1990- 130.
- Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sei. 1996- 59: 599−614.
- Matsuda M, Mori T, Sassa S et al. Chronic effect of hyperprolactinemia on blood glucose and lipids levels in mice. Life Sei. 1996- 58(14): 1171−7.
- McKenna TJ. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxford). 2009- 71: 466−69.
- Mehmet S, Powrie JK. A survey of dopamine agonist withdrawal policy in UK endocrinologists treating patients with prolactinomas. Clin Endocrinol (Oxford). 2003- 58: 111−113.
- Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003- 112: 1603−18.
- Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011- 96(2): 273−88.
- Melmed S, Kleinberg D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook oftViendocrinology. 11 ed. Philadelphia: Saunders Elsevier. 2008- 185−261.
- Mezosi E, Nemes O. Treatment of pituitary adenomas. Orv Hetil. 2009- 150(39): 1803−10.
- Mindermann T, Wilson CB. Pediatric pituitary adenomas Neurosurgery. 1995- 36(2): 259−69.
- Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998- 78: 189−225. Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992- 21: 877−901.
- Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am. 1999- 28: 143−169.
- Molitch ME. Dopamine resistance of prolactinomas. Pituitary. 2003- 6: 19−27.
- Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005- 80: 1050−57.
- Molitch ME. Pharmacological resistance in prolactinoma patients. Pitutary. 2005- 8(1): 43−52.
- Nilsson LA, Binart N, Bohlooly YM et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005- 331(4): 1120−6.
- Nilsson LA, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm MetabRes. 2009- 41: 747−751.
- Nomikos P, Buchfelder M, Fahlbusch R. Current management of prolactinomas. JNeurooncol. 2001- 54: 139−150.
- North KN, Ouvrier R.A., McLean CA, Hopkins I J. Idiopathic hypothalamic dysfunction with dilated unresponsive pupils: report of two cases. J Child Neurol. 1994- 9: 30−35.
- Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg. 2011- 114(5): 1369−79.
- Omar S, Constance L Chik, Ehud U, Shereen E. Diagnosis and management of hyperprolactinemia. Review CMAJ. 2003- 169(6): 123−5.
- Ono M, Miki N. Prolactin-producing pituitary adenoma (prolactinoma). NihonRinsho. 2011- 69(2): 131−7.
- Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008- 93: 4721−4727.
- O’Rahilly S, Farooqi IS. Genetics of obesity. Philos Trans R Soc Lond B Biol Sci. 2006- 361: 1095−1105.
- Panidis D, Rousso D, Skiadopoulos S, Panidou E, Mamopoulos M.
- Evaluation of semen parameters in man with hyperprolactinemia induced by metoclopramide. Arch Androl. 1997- 39(3): 237−242.
- Paolo A. Tomasi, Giuseppe FI, Tiziana C, Giuseppe D. Persistent Hyperprolactinemia and Bilateral Galactocele in a Male Infant. International Journal of Pediatric Endocrinology. 2009- 124−125.
- Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. Journal of Child and Adolescent Psychopharmacology. 2004- 14(3): 359−371.
- Partington MD, Davis DH, Laws ER Jr, Scheifhauer BW. Pituitary adenomas in childhood and adolescents. Results of transsphenoidal surgery. JNeurosurg. 1994- 80: 209−216.
- Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized doubleblind study. Presse Med. 1995- 24:753−757.
- Passos VQ, Souza J J, Musolino NR, Bronstein MD. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002- 87: 3578−82.
- Paturi B, Ryan RM, Michienzi KA, Lakshminrusimha S. Galactorrhea with metoclopramide use in the neonatal unit. J Perinatol. 2009- 29(5): 391−392.
- Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992- 6: 1023−1031.
- Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989- 69: 500 509.
- Perkins DO. Prolactin- and endocrine-related disorders in schizophrenia. Medical Illness and Schizophrenia / Ed. by J.M. Meyer and H.A. Nasrallah. Amer. Psychiatr. Publ. Washington, London. 2003- 215−32.
- Pernicone PJ Scheithhauer BW, Sebo TJ et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer. 1997- 79: 804−812.
- Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999- 35 Suppl: S67-S73.
- Plocinski P, Dzitko K, Dhigonska H. Prolactin as a modulator of antiparasitic immunity. Wiad Parazytol. 2007- 53(4): 263−70.
- Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol (Oxford). 1998- 49: 513−16.
- Popadiae A, Witzmann A, Buchfelder M, Eiter H, Komminoth P. Malignant prolactinoma: case report and review of the literature. Surg Neurol. 1999- 51: 47−55.
- Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol. 2012- 166(5): 779−86.
- Prior JC, Vigna YM, Wark JD et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res. 1997- 12: 1851−63.
- Raber W, Gessl A, Nowotny P, Vierhapper H. Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin. Endocrinol. 2003- 58: 185−91.
- Rains C. P, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation. Drugs. 1995- 49(2): 255−79.
- Reavley A, Fisher AD, Owen D et al. Psyhological distress in patient with hyperprolactinemia. Clin. Endocrinol. 1998- 47(3): 343−48.
- Richards RG, Hartman SM. Human dermal fibroblast cells express prolactin in vitro. J Invest Dermatol. 1996- 106: 1250−1255.
- Richelson E, Souder T, Acuna J et al. Binding studies with some new neuroleptics at human brain receptors. Biol Psychiatry. 1997- 41(7): 67−68.
- Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010- 6 pages.
- Sam S, Molitch ME. The pituitary mass: diagnosis and management. Rev Endocr Metab Disord. 2005- 6: 55−62.
- Sandoval C, Gonzalez B, Cheng S, Esquenazi Y, Mercado M.
- Macroprolactinemia identification in patients with hyperprolactinemia. Ginecol. Obstet. Mex. 2007- 75(8): 459−64.
- Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr. 2010- 73: 187−192.
- Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G. Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 1990- 13:419−22.
- Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007- 356: 29−38.
- Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett. 2005- 26: 152−159.
- Schernthaner G, Prager R, Punzengruber C, Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 1985- 28(3): 138−42.
- Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003- 349:2035−2041.
- Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab. 1983- 56:1120−3.
- Schlechte JA, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab. 1992- 75: 698−703.
- Schmid C, Goede DL, Hauser RS, Brandle M. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006- 136(15−16): 254−8.
- Sedda A, Meyer P. Management of prolactinomas: what’s new in 2010? Rev Med Suisse. 2011- 7(277): 20−4.
- Semple P, Fieggen G, Parkes J, Levitt N. Giant prolactinomas in adolescence: an uncommon cause of blindness. ChildsNerv Syst. 2007- 23: 213−17.
- Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier
- G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxford). 2006- 64(4): 366−70.
- Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. Journal of Cellular Biochemistry. 2009- 4(107): 677−685.
- Shaarawy M, El-Dawakhly AS, Mosaad M, El-Sadek MM. Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med. 1999- 37: 433−38.
- Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat Pituitary. 2009- 12: 96−104.
- Shibli-Rahhal A, Schlechte J. Hyperprolactinemia and infertility. Endocrinol Metab Clin North Am. 2011- 40(4): 837−46.
- Silva EJ, Felicio LF, Nasello AG, Zaidan-Dagli M, Anselmo-Franci JA.
- Prolactin induces adrenal hypertrophy. Braz J Med Biol Res. 2004- 37(2): 193−9.
- Sinha YN. Structural variants of prolactin: occurrence and physiological significance. EndocrRev. 1995- 16(3): 354−69.
- Sluijmer AV, Lappohn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992- 58: 72−77.
- Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med. 1992- 37: 737−740.
- Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002- 87: 5410−5415.
- Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharaiacol. 2002- 22: 109−114.
- Soran H, Wilding J, MacFarlane I. Body weight and prolactinoma: a retrospective study. Int J Obes. 2004- 28(1): 183.
- Souter I, Baltagi L, Toth T, Petrossa J. Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertility and sterility. 2010- 94(3): 1159−62.
- Spada A, Mantovani G, Lania A. Pathogenesis of prolactinomas. Pituitary. 2005- 8: 7−15.
- Teegarden D, Proulx WR, Martin BRJ, et al. Peak bone mass in young women. J Bone Miner Res. 1995- 10: 711−715.
- Thompson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery. 2002- 50: 36−39.
- Thorner MO, Vance SK, Laws ER et al. Williams Textbook of Endocrinology. 9th Ed. — Philadelphia, 1998- 249−240.
- Tokhunts KA. Comparative evaluation of effectiveness of treatment of hyperprolactinemia Russian., Georgian Med News. 2007- 142: 14−19.
- Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000- 23: 765−770.
- Traioli B, Ferrante L, Celli P. Pituitary adenomas with onset during puberty. Features and treatment. JNeurosurg. 1983- 59: 590−95.
- Trivedi P, Gupta A, Pasricha S, Patel D. Malignant prolactinoma: a rare case report. Neurol India. 2010- 58(5): 778−80.
- Tsigkaropoulou E, Peppa M, Zompola C, Rizos E, Xelioti I, Chatziioannou S, Filippopoulou A, Lykouras L. Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med. 2012- 9(1): 56−60.
- Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003- 26(4): 3416.
- Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M, Tuzcu S.
- Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009- 12: 330 334.
- Tyson D, Reggiardo D, Sklar C & David R. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. American Journal of Disease Children. 1993- 147: 1057−61.
- Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002- 87: 581−8.
- Vasilev V, Daly AF, Vroonen L, Zacharieva S, Beckers A. Resistant prolactinomas. J Endocrinol Invest. 2011- 34(4): 312−6.
- Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endo Metab. 2002- 87: 457−65.
- Viengchareun S, Bouzinba-Segard H, Laigneau JP, Zennaro MC, Kelly PA, Bado A, Lombes M, Binart N. Prolactin potentiates insulin-stimulated leptin expression and release from differentiated brown adipocytes. J Mol Endocrinol. 2004- 33: 679−691.
- Vilalta J, Topezewski T, Anez JD et al. Malformaciones arteriovenosas de fosa posterior. Clinica, tratamiento y resultados. Rev. Neurol. 2001- 12(32): 1124−28.
- Vitale G, Di Sarno A, Rota F, Lombardi G, Colao A. When can we stop cabergoline treatment in prolactinomas? Curr Opin Endocrinol Diabetes. 2003- 10: 259−264.
- Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL.1.w dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008- 159: Rll-14.
- Waldstreicher J, Duffy JF, Brown EN, Rogacz S, Allan JS, Czeisler
- CA. Gender differences in the temporal organization of proclactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels a clinical research center study. J Clin Endocrinol Metab. 1996- 81(4): 1483−7.
- Walker AM. Phosphorylated and Nonphosphorylated prolactin isoforms. Trends Endocrinol Metab. 1994- 5: 195−200.
- Wallace RB, Sherman BM, Bean JA. Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril. 1985- 43(5): 726−32.
- Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W et al. Brain dopamine and obesity. Lancet 2001- 357: 354−7.
- Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG. Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab. 1991−72:847−53.
- Weaver CM. Adolescence: the period of dramatic bone growth. Endocrine. 2002- 17: 43−48.
- Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxford). 1992- 37: 534−541.
- Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF Acomparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994- 331: 904−909.
- Wudarsky M, Nicolson R, Hamburger SD et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology. 1999- 9(4): 239−245.
- Yarman S, Tanakol R, Oguz H, Alagol F, Azizlerli H, Sandalci O. Prolactinoma: the results of surgery, post-operative radiotherapy and bromocriptine alone. Med Bull Istanbul Med Fac. 1996- 29: 46−51.
- Yavasoglu I, Kucuk M, Coskun A, Guney E, Kadikoylu G, Bolaman Z. Polycystic ovary syndrome and prolactinoma association. Intern. Med. 2009- 48(8): 611−3.
- Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic premenopausal women. Eur J Endocrinol. 2003−149:187−193.
- Yermus R, Ezzat S. Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol (Oxford). 2002- 56(4): 562.
- Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007- 356: 396.
- Zinger M, McFarland M, Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue. J Clin Endocrinol Metab. 2003- 88: 689−696.